| Literature DB >> 28777791 |
Benjamin Blasco1, Didier Leroy1, David A Fidock2,3.
Abstract
The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria. However, several Southeast Asian countries have now reported the emergence of parasites that have decreased susceptibility to artemisinin (ART) derivatives and ACT partner drugs, resulting in increasing rates of treatment failures. Here we review recent advances in understanding how antimalarials act and how resistance develops, and discuss new strategies for effectively combatting resistance, optimizing treatment and advancing the global campaign to eliminate malaria.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28777791 PMCID: PMC5747363 DOI: 10.1038/nm.4381
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440